Trials / NCT01014052
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
Completed Phase 1 Drug / neuroprotection
- Sponsor
- QLT Inc.
- Treatment
- QLT091001
- Gene
- RPE65
- Conditions
- LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
- Ages
- 5 Years to 65 Years
- Enrollment
- 32 participants
- Started
- 2009-11
- Main results expected
- 2012-08
- Results posted
- Not yet
- Record last updated
- 2013-05-14
What the study is testing
The purpose of this study is:
- to evaluate the safety of oral QLT091001
- to evaluate whether 7-day treatment with oral QLT091001 can improve visual function in subjects with LCA or RP due to RPE65 or LRAT mutations
- to evaluate duration of visual function improvement (if observed)
Where it runs
Canada (1)
- Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec
Germany (1)
- Institute for Ophthalmic Research, University of Tubingen, Tübingen
Netherlands (1)
- The Rotterdam Eye Hospital, Rotterdam
United Kingdom (1)
- Moorefield Eye Hospital, London
United States (3)
- The Chicago Lighthouse for People Who Are Blind or Visually Impaired (The Pangere Center For Inherited Retinal Diseases), Chicago, Illinois
- Wilmer Eye Institute (Johns Hopkins University), Baltimore, Maryland
- Scheie Eye Institute, Philadelphia, Pennsylvania